SCHEMBL4778153

SCHEMBL4778153

CCC(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
POLB P06746 1/20 0.69
ME2 P23368 1/20 0.62
ME1 P48163 1/20 0.62
ME3 Q16798 1/20 0.62
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA9 Q16790 1/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
GFER P55789 1/20 0.61
MAPT P10636 1/20 0.61
LMNA P02545 1/20 0.61
L3MBTL1 Q9Y468 2/20 0.60
CNR1 P21554 1/20 0.60
CNR2 P34972 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HPGD P15428 2/20 0.59
HSD17B10 Q99714 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21084409 0.87 CNR1 (0.68) ALDH1A1POLBME2ME1ME3
SCHEMBL14524661 0.85 MAPT (0.67) POLBME2ME1ME3KMT2A
SCHEMBL16994768 0.85 MEN1 (0.63) ALDH1A1POLBMEN1KMT2AGFER
SCHEMBL2878977 0.83 POLB (0.69) ALDH1A1POLBME2ME1ME3
SCHEMBL17021274 0.83 AKR1C3 (0.58) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL1813106 0.83 GFER (0.68) ALDH1A1POLBMEN1KMT2AGFER
SCHEMBL14489710 0.83 POLB (0.69) ALDH1A1POLBME2ME1ME3
SCHEMBL2235816 0.83 MAPT (0.57) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL12419699 0.83 AKR1C3 (0.68) ALDH1A1POLBME2ME1ME3
SCHEMBL12781874 0.83 MAPT (0.70) ALDH1A1MEN1KMT2AGFERMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE SHY Therapeutics LLC 2017-06-22 US disclosed
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS THE INSTITUTE OF MOLECULAR MEDICINE (IN) 2011-03-10 US disclosed
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS THE INSTITUTE OF MOLECULAR MEDICINE (IN) 2011-03-10 US disclosed
WO-2009091324-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS CHATTOPADHYAYA JYOTI (SE) 2009-07-23 WO disclosed
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059948-A1 QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS NQO1, NQO2, NDUFV1 ALDH1A1 1830/4885POLB 326/4885ME2 70/4885
US-20170174699-A1 COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE MAPK6, MAP3K6, MAPK4 ALDH1A1 2765/4885POLB 1589/4885ME2 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.